DMT
Disease Modifying Therapies
Thursday, June 2, 2022: 2:30 PM-4:30 PM
Woodrow Wilson D (Gaylord National Resort & Convention Center)
2:30 PM
Treatment-Emergent COVID-19 in Ozanimod Multiple Sclerosis and Ulcerative Colitis Clinical Trials
Bruce A.C. Cree, MD, PhD, Weill Institute for Neurosciences, University of California San Francisco;
Ryan C. Ungaro, MD, Icahn School of Medicine at Mount Sinai;
Jean-Frederic Colombel, MD, Icahn School of Medicine at Mount Sinai;
Corey A. Siegel, MD, MS, Dartmouth-Hitchcock Medical Center;
James K. Sheffield, MD, Bristol Myers Squibb;
John Vaile, PharmD, Bristol Myers Squibb;
Harris A. Ahmad, MD, Bristol Myers Squibb;
Ashwini Pai, MD, Bristol Myers Squibb;
Shabana Ather, MD, Bristol Myers Squibb;
Lorna Charles, MD, Bristol Myers Squibb;
AnnKatrin Petersen, MD, Bristol Myers Squibb;
Chun-Yen Cheng, PhD, Bristol Myers Squibb;
Sonia Afsari, MD, Bristol Myers Squibb;
Krzysztof W. Selmaj, MD, Center for Neurology, Łódź, Poland, and Department of Neurology, University of Warmia & Mazury
2:50 PM
Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a Phase II Trial
Xavier Montalban, MD PhD, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron;
Jerry S Wolinsky, MD, The University of Texas Health Science Center at Houston (UTHealth);
Douglas L Arnold, MD, McGill University, NeuroRx Research;
Martin S Weber, MD, University of Göttingen;
Ivan Staikov, MD PhD, Acibadem City Clinic Tokuda Hospital;
Karolina Piasecka-Stryczynska, PhD, Poznań University of Medical Sciences;
Davorka Tomic, PhD, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany;
Emily C Martin, PhD, EMD Serono;
Kristina H Holmberg, PhD, EMD Serono;
Hans Guehring, MD, The healthcare business of Merck KGaA
3:10 PM
Reduced Disease Progression with Ublituximab Vs Teriflunomide in the Phase 3 Ultimate I and II Studies in Relapsing Multiple Sclerosis
Enrique Alvarez, MD, PhD, University of Colorado;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
Edward J Fox, MD, PhD, Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas;
Hans-Peter Hartung, MD, Heinrich Heine University, Brain and Mind Centre, University of Sydney, Medical University of Vienna, Palacky University;
Peiqing Qian, MD, Swedish Medical Center;
Sibyl Wray, MD, Hope Neurology MS center;
Derrick Robertson, MD, University of South Florida;
DeRen Huang, MD, PhD, Mount Carmel Health System;
Krysztof Selmaj, MD, PhD, Center of Neurology, University of Warmia & Mazury;
Daniel Wynn, MD, Consultants in Neurology MS Center;
Lily Lee, PhD, TG Therapeutics;
Bruce A Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco
3:30 PM
Longer-Term Safety of Ofatumumab in Patients with Relapsing Multiple Sclerosis
Jacqueline A Nicholas, MD, MPH, OhioHealth Multiple Sclerosis Center;
Stephen L Hauser, PhD, UCSF Weill Institute for Neurosciences, University of California;
Anne H Cross, MD, Washington University School of Medicine;
Kevin Winthrop, MD, MPH, Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University;
Heinz Wiendl, MD, MPH, University of Muenster;
Sven G Meuth, MD, PhD, Department of Neurology, Medical Faculty, Heinrich-Heine-University;
Paul S Giacomini, MD, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University;
Francesco Sacca, MD, NSRO Department, University “Federico II” of Naples;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Xixi Hu, PhD, Novartis Pharmaceuticals Corporation;
Ayan Das Gupta, Msc, Novartis Healthcare Pvt. Ltd;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Virginia DeLas Heras, MD, Novartis Pharma AG;
Wendy Su, PhD, Novartis Pharmaceuticals Corporation;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel
3:50 PM
Benefits of Repeated Confirmed Disability Progressions Analyses in MS Clinical Trials: A Case Study Using the Opera and Oratorio Trials and Their Open-Label Extensions
Jerry S Wolinsky, MD, The University of Texas Health Science Center at Houston (UTHealth);
Hans-Peter Hartung, MD, Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich Heine University Düsseldorf, Brain and Mind Centre, University of Sydney;
Stephen L. Hauser, MD, University of California San Francisco;
Robert T. Naismith, MD, Washington University School of Medicine;
Hans-Martin Schneble, MD, F. Hoffmann-La Roche Ltd;
Ben Townsend, PhD, F. Hoffmann-La Roche Ltd;
Qing Wang, PhD, F. Hoffmann-La Roche Ltd;
Ludwig Kappos, PhD, University Hospital Basel, University of Basel
4:10 PM
Perceptions and Discussions on the Use of Disease-Modifying Therapies during Family Planning in Women with Multiple Sclerosis
Riley Bove, MD, Weill Institute for Neurosciences, University of California San Francisco;
Noemi Pasquarelli, MSc, PhD, F. Hoffmann-La Roche Ltd;
Marina Gafarova, MD, PhD, Roche Moscow JSC;
Christine Eighteen, MBA, F. Hoffmann-La Roche Ltd;
Natalie Joschko, PhD, Roche Pharma AG;
Corey Mandel, PhD, Genentech, Inc.;
Ruth Dobson, PhD, FRCP, Wolfson Institute of Preventive Medicine, Queen Mary University of London
